[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615392":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":34,"locations":44,"responsibleParty":133,"collaborators":21,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":137,"sex":143,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":21,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":65,"whyStopped":21,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mirikizumab treatment","EXPERIMENTAL","Mirikizumab will be used as scheduled in the drug label: induction with IV infusions (900 mg) at week 0, week 4 and week 8.\n\nFor clinical responders: SC injections (300 mg) at W12 and every 4 weeks For clinical non-responders: SC injections (300 mg) at W12 and every 4 weeks",[13,14],"Drug: Mirikizumab - IV","Drug: Mirikizumab - SC",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Mirikizumab - IV","Mirikizumab induction with IV infusions (900 mg) at week 0, week 4 and week 8.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Mirikizumab - SC","SC injections (300 mg) at W12 and every 4 weeks For clinical responders and non-responders",[9],[27,31],{"name":28,"affiliation":29,"role":30},"Anthony BUISSON, MD","University Hospital, Clermont-Ferrand","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":33,"role":30},"Guillaume LE COSQUER, MD","CHU de Toulouse- Hôpital Rangueil",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":21,"email":39},"Julie MUSSOT","CONTACT","+33 6 27 49 29 10","jmussot@getaid.org",{"name":41,"role":37,"phone":42,"phoneExt":21,"email":43},"Noemie DA COSTA","+33 9 72 57 61 60","ndacosta@getaid.org",[45,63,77,91,105,119],{"facility":46,"status":47,"city":48,"state":21,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"CHU de Brest - Hôpital de la Cavale Blanche","NOT_YET_RECRUITING","Brest","29200","France","FR",{"type":53,"coordinates":54},"Point",[55,56],-4.48628,48.39029,{"lat":56,"lon":55},[59],{"name":60,"role":37,"phone":61,"phoneExt":21,"email":62},"Franck CHOLET, MD","+33 2 98 34 71 15","franck.cholet@chu-brest.fr",{"facility":64,"status":65,"city":66,"state":21,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"CHU de Clermont Ferrand - Hôpital d'Estaing","RECRUITING","Clermont-Ferrand","63003",{"type":53,"coordinates":69},[70,71],3.08682,45.77969,{"lat":71,"lon":70},[74],{"name":28,"role":37,"phone":75,"phoneExt":21,"email":76},"+33 4 73 75 05 23","a_buisson@chu-clermontferrand.fr",{"facility":78,"status":47,"city":79,"state":21,"zip":80,"country":50,"countryCode":51,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"CHU de Nîmes Carémeau","Nîmes","30029",{"type":53,"coordinates":82},[83,84],4.35788,43.83665,{"lat":84,"lon":83},[87],{"name":88,"role":37,"phone":89,"phoneExt":21,"email":90},"Ludovic CAILLO, MD","+33 4 66 68 31 83","Ludovic.CAILLO@chu-nimes.fr",{"facility":92,"status":47,"city":93,"state":21,"zip":94,"country":50,"countryCode":51,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Institut Mutualiste Monsouris","Paris","75674",{"type":53,"coordinates":96},[97,98],2.3488,48.85341,{"lat":98,"lon":97},[101],{"name":102,"role":37,"phone":103,"phoneExt":21,"email":104},"Marion SIMON, MD","+33 1 56 61 63 14","Marion.Simon@imm.fr",{"facility":106,"status":47,"city":107,"state":21,"zip":108,"country":50,"countryCode":51,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"CHU de Toulouse - Hôpital Rangueil","Toulouse","31059",{"type":53,"coordinates":110},[111,112],1.44367,43.60426,{"lat":112,"lon":111},[115],{"name":116,"role":37,"phone":117,"phoneExt":21,"email":118},"Cyrielle GILLETTA, MD","+33 5 61 32 27 63","gilletta.c@chu-toulouse.fr",{"facility":120,"status":47,"city":121,"state":21,"zip":122,"country":50,"countryCode":51,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"CH de Valence","Valence","26000",{"type":53,"coordinates":124},[125,126],4.90956,44.9256,{"lat":126,"lon":125},[129],{"name":130,"role":37,"phone":131,"phoneExt":21,"email":132},"Céline MONTUCLARD, MD","+33475757512","cmontuclard@ch-valence.fr",{"type":134,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100615392","phase-4-efficacy-of-mirikizumab-to-achieve-transmural-healing-in-patients-with-crohns-disease-100615392",false,"NCT07292012","Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease","Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD","EMINENT-CD","Inclusion Criteria:\n\n* Patients with CD\n* ≥ 18 to ≤ 75 years-old\n* Symptomatic CD according to PRO-2 (stool \\> 3 or abdominal pain score \\> 1)\n* Transmural inflammation on baseline MRI (C-score \\> 0.5 in at least one segment)\n\nExclusion Criteria:\n\n* Prior exposure to anti-p19 biological therapy\n* Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase \\[JAK\\] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents\n* Exclude any previous use of p19 IL23s agents\n* Contra-indication to mirikizumab\n* Definitive ostomy\n* Colectomy with IPAA\n* Isolated or uncontrolled perianal lesions\n* Severe obstructive symptoms\n* Intra-abdominal abscess\n* Contra-indication to MRI\n* No health insurance\n* Pregnant or lactating women\n* Patients already included in biomedical research other than an observational study (e.g., registry, cohort)\n* Concomitant Clostridioides difficile infection\n* HIV infection\n* Patient under guardianship, curatorship or safeguard of justice","ALL","18 Years","75 Years",{"count":147,"type":148},75,"ESTIMATED","INTERVENTIONAL",[151],"PHASE4","Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease",[154],"Crohn Disease (CD)",[156,157,158],"crohn's disease","transmural healing","mirikizumab","2026-05-21",{"date":161,"type":162},"2026-05-26","ACTUAL",{"date":164,"type":162},"2026-05-11",{"date":166,"type":148},"2028-11",{"name":5,"class":6},6]